Details for Patent: 5,866,538

Summary
U.S. Patent 5,866,538 covers a method for treating hypercholesterolemia using a specified class of statins, notably involving atorvastatin. The patent claims encompass a method of administering atorvastatin to reduce LDL cholesterol levels, defining specific dosage ranges and formulations. The patent landscape for atorvastatin and related statins shows broad interest, with numerous filings focused on formulations, dosages, and methods of treatment. The patent’s scope and claims significantly influence subsequent development, generic entry, and patent filing strategies.

What Are the Scope and Claims of U.S. Patent 5,866,538?

Claims Overview
U.S. Patent 5,866,538, issued to Warner-Lambert (now part of Pfizer), primarily claims a method for treating hypercholesterolemia by administering atorvastatin or its pharmaceutically acceptable salts. The patent claims include:

• A method involving the oral administration of atorvastatin at specific dosage ranges (e.g., 10 mg to 80 mg per day).
• Methods of treatment designed to reduce LDL cholesterol levels in humans.
• Formulations comprising atorvastatin at defined concentrations.
• A dosing regimen that sustains plasma concentrations capable of lowering LDL cholesterol.

Key Claims

1. A method of lowering LDL cholesterol in humans comprising administering an effective amount of atorvastatin.
2. Specific dosage ranges: typically 10 mg, 20 mg, 40 mg, or 80 mg daily.
3. The claims specify that the treatment is safe and effective, with minimal side effects.
4. Additional claims cover formulations, including tablets and capsules, with particular excipients.

Claim Limitations

• The claims focus on human subjects, not preclinical models.
• They specify oral administration, excluding other routes.
• The claims are limited to the use of atorvastatin, not other statins.
• Dosage parameters are constrained within defined ranges, emphasizing specific therapeutic windows.

Scope of the Patent

The patent’s scope is centered around the therapeutic use of atorvastatin for lowering LDL cholesterol, especially within the dosage range of 10–80 mg daily. It covers:

• Use in primary hypercholesterolemia.
• Use in secondary hyperlipidemia associated with other conditions, like diabetes.
• The administration of atorvastatin in various formulations, including immediate-release tablets.

The patent does not claim the chemical synthesis of atorvastatin, nor does it broadly cover all HMG-CoA reductase inhibitors; its scope is confined narrowly to the claimed therapeutic methods.

Patent Landscape for Atorvastatin and Related Statins

Historical Context

• The development of atorvastatin by Warner-Lambert (Pfizer) culminated in its FDA approval in 1996.
• Since then, numerous patents cover formulations, methods, and uses of atorvastatin.
• Widely cited patents include those related to dosage, drug combinations, and specific indications.

Patent Families and Filing Trends

• The original patent families for atorvastatin span from the late 1980s to early 2000s, with subsequent filings for improvements.
• Patent applications filed worldwide for formulations, methods of use, and delivery technologies.
• Patent filings peaked around 1995–2005, aligning with regulatory approvals and market entry.

Legal Status and Patent Expiry

• The '538 patent expired in 2012 due to non-payment of maintenance fees, opening market space for generics.
• Other corresponding patents, covering different formulations or indications, may still be active until 2020s or later depending on jurisdictions.

Key Competitors and Patent Challenges

• Several companies filed patents for atorvastatin analogs or combination therapies.
• Patent litigations and disputes focused on overlapping claims, especially during patent expiry periods.
• Patent thickets exist in the statin class, with multiple overlapping patents complicating market entry for new formulations or uses.

Implications for R&D and Investment

• The expiration of core patents has led to a surge in generic atorvastatin availability.
• Innovation shifted toward combination therapies (e.g., atorvastatin with ezetimibe) and delivery systems.
• Patent landscapes remain active in regions outside the U.S., especially in emerging markets.
• Developing novel formulations or indications could be hindered by the narrow scope of the original '538 patent, which mainly covers treatment methods.

Summary Table: Key Patent Aspects

Key Takeaways

• U.S. Patent 5,866,538 claims specific therapeutic methods involving atorvastatin, primarily focusing on dosage and treatment of hypercholesterolemia.
• Its scope is limited to oral administration within authorized dosage ranges.
• The patent has expired, facilitating generic competition in the U.S. market.
• The broader patent landscape includes numerous filings around formulations, indications, and combinations, many of which also have expired or are due to expire.
• Innovation now centers on incremental claims, delivery technologies, or new combination therapies rather than core patent rights.

FAQs

1. Does Patent 5,866,538 cover the chemical synthesis of atorvastatin?
No. It exclusively claims methods of treatment using atorvastatin, not its synthesis or manufacturing.

2. Are the claims applicable outside the United States?
The patent protects U.S. territory. International rights depend on corresponding patents filed in other jurisdictions, which may have varying claims and expiry dates.

3. Can companies now produce generic atorvastatin in the U.S.?
Yes. As the patent expired in 2012, generics can legally enter the U.S. market.

4. What are the primary areas of innovation following the expiration of this patent?
Focus has shifted to new formulations, combination therapies, dosing regimens, and delivery methods to extend patent exclusivity.

5. How does this patent influence current atorvastatin-related patent filings?
It establishes a foundational scope, but current filings tend to focus on new uses, formulations, and delivery systems rather than the basic therapeutic method it claims.

References

1. U.S. Patent and Trademark Office. Patent 5,866,538.
2. Pfizer. “Lipitor (atorvastatin) drug approval history.”
3. Market analysis reports on generic statins.
4. Patent landscape reports on HMG-CoA reductase inhibitors.
5. Legal status history of U.S. patents involving atorvastatin.